Welcome to our dedicated page for Greenland Mines SEC filings (Ticker: KLTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Greenland Mines's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Greenland Mines's regulatory disclosures and financial reporting.
Greenland Mines Ltd, formerly Klotho Neurosciences, is hosting a publicly accessible investor webcast on March 12, 2026, to present its new strategy and assets. The company recently completed the acquisition of Greenland Mines on March 4, 2026, paying consideration in convertible preferred equity subject to shareholder approval.
Following the deal, the business now operates two divisions: Natural Resources and Cell and Gene Therapy. Greenland Mines owns 80% of the Skaergaard Project in southeast Greenland, with an option on the remaining 20%. A 2022 NI 43-101 report shows 25.4 Moz PdEq and 23.5 Moz AuEq, with an estimated in-situ resource value of about $68 billion at February 2026 metal prices. A new drilling and development program aims to double the resource to roughly 50 million contained ounces of gold, palladium, and platinum.
Klotho Neurosciences, Inc. completed a stock-for-stock acquisition of Greenland Mines Corp., which now operates as a wholly owned subsidiary holding an 80% interest in Major Precious Greenland A/S and the Skaergaard mineral project in Greenland. Former Greenland Mines stockholders received 47,000 shares of newly created Series C Preferred Stock and may designate one director to Klotho’s board. The Series C Preferred totals 50,000 authorized shares, carries dividends on an as-converted basis, gains voting rights only after stockholder approval, and then becomes convertible, with each preferred share exchangeable into 42,554 common shares. Mineral resource figures for Skaergaard are based on a 2022 NI 43-101 Technical Report prepared by SLR Consulting and have not been independently verified by the company.
Klotho Neurosciences, Inc. reported that Chief Financial Officer Jeff LeBlanc acquired 2,500,000 shares of common stock on a grant/award basis. The shares were received at a price of $0.00 per share as a grant under the company’s Equity Incentive Plan, meaning no cash purchase was involved.
Following this equity award, LeBlanc directly holds 3,420,342 common shares of Klotho Neurosciences. This filing records an increase in his equity-based compensation and ownership stake through the company’s incentive program.
Klotho Neurosciences, Inc. director El-Dada Riad Hussein reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded under the company’s Equity Incentive Plan and were acquired at a stated price of $0.00 per share.
ZENTMAN SAMUEL M reported acquisition or exercise transactions in this Form 4 filing.
Klotho Neurosciences, Inc. director Samuel M. Zentman reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded at a stated price of $0.00 per share as a grant under the company’s Equity Incentive Plan.
Following this equity award, Zentman’s directly held Common Stock increased to 1,086,440 shares. This filing reflects a non-cash stock grant that further aligns the director’s ownership with the company’s performance.
Klotho Neurosciences, Inc. reported that director Shalom Hirschman acquired 350,000 shares of Common Stock on March 4, 2026. The shares were received as a grant under the company’s Equity Incentive Plan and carried a stated price of $0.00 per share.
Following this equity award, Hirschman’s direct ownership increased to 908,873 shares of Common Stock, according to the Form 4 disclosure.
McGarity Jon reported acquisition or exercise transactions in this Form 4 filing.
Klotho Neurosciences, Inc. director Jon McGarity reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were granted under the company’s Equity Incentive Plan and carried a reported price of $0.00 per share, indicating a non-cash equity award. Following this grant, McGarity’s directly held Common Stock increased to 411,277 shares, aligning his compensation more closely with shareholder interests through additional stock-based incentives.
Klotho Neurosciences, Inc. reported that Chief Executive Officer Joseph Sinkule acquired 2,500,000 shares of common stock on March 4, 2026 through a grant under the company’s Equity Incentive Plan. The shares were reported at a price of $0.00 per share.
Following this grant, Sinkule’s directly held common stock increased to 6,346,700 shares. This transaction reflects an equity award rather than an open-market purchase or sale.
Klotho Neurosciences, Inc. is acquiring privately held Greenland Mines Corp., which controls an 80% interest in, and an option for the remaining 20% of, the Skaergaard palladium‑gold‑platinum project in Southeast Greenland. The deal consideration is payable in convertible preferred stock, and on an as‑converted basis Greenland Mines is expected to own about 93% of fully diluted shares, with the transaction treated as a reverse merger for accounting purposes. Klotho will operate two divisions, Natural Resources and Cell and Gene Therapy, and plans to change its name and ticker to reflect the Greenland Mines focus. Skaergaard hosts an NI 43‑101 Indicated and Inferred Mineral Resource of 25.4 million ounces palladium equivalent and 23.5 million ounces gold equivalent with an illustrative gross in‑situ metal value of roughly $68 billion based on February 2026 metal prices, though no economic study has yet demonstrated project viability.
Klotho Neurosciences, Inc. completed a private financing on March 2, 2026 under a Securities Purchase Agreement dated February 19, 2026. The company issued 34,551,939 shares of common stock and Warrants to purchase up to an additional 34,551,939 shares, raising aggregate gross proceeds of approximately $7,750,000.
The transaction was conducted as a private placement to accredited investors under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, without general solicitation or advertising. The Warrants and their terms are described in an earlier filing, with a form of Warrant filed as an exhibit.